MST Financial is proud to have acted as Sole Lead Manager for Alterity Therapeutics (ATH.ASX) A$40.0 million capital raising.
Funds raised will be used to strengthen Alterity’s balance sheet, accelerate the clinical development of ATH434 in Multiple System Atrophy (MSA), and support ongoing research into other neurodegenerative diseases, including Parkinson’s. The funding will also provide balance sheet flexibility as the company pursues partnership opportunities.